July 2017 P&T Updates

Similar documents
May 2017 P&T Updates

March 2018 P & T Updates

March 2017 P&T Updates

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018

November 2018 P & T Updates

Neighborhood Medicaid Formulary Changes: June 2017

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

The safety and effectiveness of Dupixent in pediatric patients have not been established (1).

January 2018 P & T Updates

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

Eucrisa. Eucrisa (crisaborole) Description

Eucrisa. Eucrisa (crisaborole) Description

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

Step Therapy Medications

35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution.

Rationale for Decision Excluded Generic OTC equivalent available (Flonase Allergy Relief) Medicare status (if differs)

Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:

2018 Step Therapy (ST) Criteria

GA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy

San Francisco Health Plan (SFHP)

See Important Reminder at the end of this policy for important regulatory and legal information.

Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)

LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION

Quarterly pharmacy formulary change notice

1/1/2019 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary October 1, 2018 Updates. Formulary. Alternatives

May 2016 P & T Updates

MEDICAL ASSISTANCE BULLETIN

Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications

See Important Reminder at the end of this policy for important regulatory and legal information.

Oral Oncology Agents. August 2017 Update. SGLT-2 Category Update. Removal of Medical Foods

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications

Cerebral Stimulant and ADHD Drugs Prior Authorization Request

Pharmacy Updates Summary

WellCare s South Carolina Preferred Drug List Update

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions

2018 Medicare Part D Formulary Change

ANTICONVULSANTS. Details. Step Therapy Criteria Date Effective: April 1, 2019

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications

ELEVATE. Formulary Updates to Elevate Plans (Bronze HDHP/Standard, Silver Select/Standard & Gold Select/Standard)

Aetna Better Health of Illinois Medicaid Formulary Updates

2018 Medicare Part D Formulary Change

Reason for change. Recently approved. Recently approved. Recently approved. Recently approved. Recently updated. Recently approved.

Effective for all members on August 1, 2017

**CRITERIA UNDER CMS REVIEW**

Pharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS

2018 CareOregon Advantage Part D Formulary Changes

AD/HD is a mental disorder, and it often lasts from

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS

2017 Formulary Addendum Notice of Change

Step Therapy Criteria 2019

Central Nervous System Stimulants Drug Class Prior Authorization Protocol

BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS

2017 Formulary Addendum Notice of Change (Prescription Drug Plans)

2017 Formulary Addendum Notice of Change

Dupixent (dupilumab)

Drug Formulary Update, January 2013

UPDATE Ohana QUEST Integration Medicaid

San Francisco Health Plan (SFHP)

Health Partners Medicare Prime 2019 Formulary Changes

Big Lots Behavioral Health. Prescribing Guidelines for Behavioral Health

Emblem Medicaid 3Q18 Formulary Updates

Your prescription benefit updates Formulary Updates - Effective January 1, 2019

ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR

Alprazolam 0.25mg, 0.5mg, 1mg tablets

HMO and PPO Updates September Commercial Results

The Medical Letter. on Drugs and Therapeutics

The Latest Prescription Trends for Controlled Prescription Drugs

Health New England (HNE) is making some changes to your Plan, most of which become effective July 1, 2015.

Stimulants. The psychostimulants, or more simply known as stimulants, are used primarily in treating attention-deficit/ Dosing Information

2017 Formulary Addendum Notice of Change (Medicare Advantage Plans)

Pharmacologic Treatment of Atopic Dermatitis

2017 Formulary Addendum Notice of Change

PHARMACY AND THERAPEUTICS COMMITTEE August 2016

Pharmacy Formulary Updates for January 2019

See Important Reminder at the end of this policy for important regulatory and legal information.

2017 Step Therapy (ST) Criteria

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

2018 Formulary Update

Update to HMO Drug Formulary Tier Definitions. February 8, 2018

OH Gold PPO /50 Metallic Level: Gold. $500 copay per admission after deductible. T1A-$3 copay plus 30% T1-$10 copay plus 30%

Topical Immunomodulators

2017 Formulary Addendum Notice of Change (Medicare Advantage Plans)

ALOGLIPTIN STEP. Step Therapy Requirements Effective April 1, 2018

ALOGLIPTIN STEP. Step Therapy Requirements Effective June 1, 2018

ALLERGIC RHINITIS-NASAL

You ll find the most up-to-date comprehensive version of our formulary on our website, Click on Drug Finder.

FlexRx 6-Tier. SM Pharmacy Benefit Guide

DRUG TREND REPORT. WellDyneRx ANNUAL 1 2% 34% WellDyneRx. Diabetes MS Oncology Asthma/COPD HIV. Pain/inflammation. High Blood Choles Attention Disorde

Pharmacy Benefit Determination Policy

2017 Formulary Addendum Notice of Change (Medicare Advantage Plans)

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

2017 Medicare Part D Formulary Change

2019 Formulary Update

Kentucky Medicaid will incorporate the following changes to its PDL on June 11, 2014:

Big Lots Behavioral Health. Prescribing Guidelines for Behavioral Health

Transcription:

July 2017 P&T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth Alternatives ALUNBRIG 3 2 DUPIXENT Pharmacy 3 2 6 tablets per day, 30 day One-week auth for QL of 3 syringes per 28 Remainder of the 6 month auth duration, QL of 2 syringes per 28 Then, 2/28 Elidel*, topical prednisone, prednisolone EUCRISA 3 No 2 No - prednisolone, prednisone ISENTRESS HD 2 No 2 No 2 tablets per day - RILUZOLE 1 No 1 No No - none RYDAPT 3 2 STIVARGA 3 2 AML: 56 capsules per 21 SM: 112 capsules per 28 84 tablets per 28 Systemic Mastocytosis: imatinib 1 No 1 No No - - No 1 tablet per day Amitiza, Linzess - XERMELO 3 2 ZEJULA 3 2 3 tablets per day, 28 day 3 tablets per day, 30 day octreotide, Somatuline Depot*

CHIP Tier Prior Auth ALUNBRIG 2 DUPIXENT Pharmacy 2 6 tablets per day, 30 day One-week auth for QL of 3 syringes per 28 Remainder of the 6 month auth duration, QL of 2 syringes per 28 Alternatives Elidel*, prednisone, prednisolone Then, 2/28 topical EUCRISA 2 No - prednisolone, prednisone ISENTRESS HD 2 No 2 tablets per day - RILUZOLE 2 No No - none AML: 56 capsules per 21 RYDAPT 2 SM: 112 capsules per 28 Systemic Mastocytosis: imatinib STIVARGA 2 84 tablets per 28-2 No No - - - 1 tablet per day Amitiza, Linzess XERMELO 2 3 tablets per day, 28 day octreotide, Somatuline Depot* ZEJULA 2 3 tablets per day, 30 day

GHP Family GHP Family Tier Prior Auth Alternative(s) ALUNBRIG Brand 6 tablets daily Xalkori*, Alcensa*, Zykadia* ATOMOXETINE Generic No 10 mg, 100 mg, 40 mg, 60 mg, 80 mg one capsule daily, 18 mg two capsules daily, 25 mg three capsules daily DUPIXENT Brand 2 syringes per 28 EUCRISA Brand No - Methylphenidate, Methylphenidate ER, Amphetamine Salt Combo, Amphetamine- Dextroamphetamine, Amphetamine- Dextroamphetamine ER, Guanfacine ER tacroliumus ointment, Elidel* tacroliumus ointment, Elidel* FOSRENOL PACKETS Brand No No - Fosrenol Tablets, Renagel ISENTRESS HD Brand No two tablets daily Isentress Tablet, Isentress Chewable Tablet LINZESS Brand No - Amitiza* OCTREOTIDE Generic No No - e RILUZOLE Generic No No - e RYDAPT Brand AML - 56 capsules per 21, SM - 112 capsules per 28 imatinib* STIVARGA Brand 84 tablets per 28 e Generic No No - Elidel* one tablet daily Amitiza*, Linzess* XERMELO Brand three tablets daily octrotide ZEJULA Brand 3 tablets daily Beginning August 15th, any prescription for greater than a 7 day supply of opioids for anyone age 17 or younger will require prior authorization. Beginning September 15th, any prescription for a greater than 14 day supply of opioids for anyone age 18 and older will require prior authorization. Beginning September 15th, any high dose of opioids will require prior authorization. Beginning November 1, new opioid quantity limits will be effective. Please call 855-552- 6028 for details.

Geisinger Gold $0 Deductible ALUNBRIG Specialty DUPIXENT Specialty EUCRISA Brand Preferred IMFINZI Specialty ISENTRESS HD Specialty RADICAVA Specialty RYDAPT Specialty Standard Prior Auth 6 tablets/day 8 ml in 28 - - - - Alternative(s) clobetasol, halobetasol, clobetasol, halobetasol, Bavencio*, Keytruda*, Opdivo*, Tecentriq* No 2 tablets/day Isentress 2800 mls every 28 112 capsules per 28 riluzole Imatinib Generic No - - alclometasone, clobetasol, desonide, diflorasone, fluocinolone, fluticasone, halobetasol, mometasone, XERMELO Specialty ZEJULA Specialty - - - - - Amitiza, Linzess 3 tablets/day octreotide, Somatuline Depot 3 tablets/day

Marketplace Tier Prior Auth ALUNBRIG 5 DUPIXENT Pharmacy 5 6 tablets per day, 30 day One-week auth for QL of 3 syringes per 28 Remainder of the 6 month auth duration, QL of 2 syringes per 28 Alternatives Elidel*, topical prednisone, prednisolone Then, 2/28 EUCRISA 4 No - prednisolone, prednisone ISENTRESS HD 3 No 2 tablets per day - RILUZOLE 2 No No - none RYDAPT 5 AML: 56 capsules per 21 SM: 112 capsules per 28 Systemic Mastocytosis: imatinib STIVARGA 5 84 tablets per 28-2 No No - - 1 tablet per day Amitiza, Linzess XERMELO 5 3 tablets per day, 28 day octreotide, Somatuline Depot* ZEJULA 5 3 tablets per day, 30 day